OncoMatch/Clinical Trials/NCT06884618
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Official title: A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
Is NCT06884618 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies RO7673396 for neoplasms.
Treatment: RO7673396 — This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HRAS mutation
Required: KRAS mutation
Required: NRAS mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate hematologic function
Liver function
Adequate end-organ function
Adequate hematologic and end-organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCHealth Lung Cancer Clinic - Anschutz Medical Campus - PPDS · Aurora, Colorado
- Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
- Florida Cancer Specialists - Sarasota (North Catttlemen Rd) · Sarasota, Florida
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06884618 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require HRAS?
Yes, HRAS mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify